- Home
- TWFG vs MGTX Comparison
TWFG vs MGTX Comparison
Compare TWFG & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TWFG
- MGTX
- Stock Information
- Founded
- TWFG 2001
- MGTX 2015
- Country
- TWFG United States
- MGTX United States
- Employees
- TWFG N/A
- MGTX N/A
- Industry
- TWFG
- MGTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TWFG
- MGTX Health Care
- Exchange
- TWFG NYSE
- MGTX Nasdaq
- Market Cap
- TWFG 521.8M
- MGTX 622.0M
- IPO Year
- TWFG 2024
- MGTX N/A
- Fundamental
- Price
- TWFG $29.37
- MGTX $7.65
- Analyst Decision
- TWFG Buy
- MGTX Strong Buy
- Analyst Count
- TWFG 8
- MGTX 2
- Target Price
- TWFG $35.57
- MGTX $24.00
- AVG Volume (30 Days)
- TWFG 68.7K
- MGTX 673.2K
- Earning Date
- TWFG 08-12-2025
- MGTX 08-11-2025
- Dividend Yield
- TWFG N/A
- MGTX N/A
- EPS Growth
- TWFG N/A
- MGTX N/A
- EPS
- TWFG N/A
- MGTX N/A
- Revenue
- TWFG $211,440,000.00
- MGTX $34,508,000.00
- Revenue This Year
- TWFG $23.90
- MGTX $228.65
- Revenue Next Year
- TWFG $22.60
- MGTX $145.06
- P/E Ratio
- TWFG N/A
- MGTX N/A
- Revenue Growth
- TWFG 18.57
- MGTX 203.23
- 52 Week Low
- TWFG $22.93
- MGTX $3.85
- 52 Week High
- TWFG $36.85
- MGTX $8.98
- Technical
- Relative Strength Index (RSI)
- TWFG N/A
- MGTX 46.02
- Support Level
- TWFG N/A
- MGTX $8.32
- Resistance Level
- TWFG N/A
- MGTX $8.31
- Average True Range (ATR)
- TWFG 0.00
- MGTX 0.39
- MACD
- TWFG 0.00
- MGTX -0.19
- Stochastic Oscillator
- TWFG 0.00
- MGTX 13.36
About TWFG TWFG INC
TWFG Inc is a independent distribution platform for personal and commercial insurance in the United States. It offers all lines of insurance, multiple distribution contract options, M&A services, proprietary virtual assistants, proprietary technology, proprietary premium financing, unlimited continuing education, recognition programs, co-op funding, marketing support and overall lower costs to operate.
About MGTX MeiraGTx Holdings plc
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.